Table 3.
Univariate analysis of transplant outcomes
| Variables | LFS | OS | Incidence of relapse | Nonrelapse mortality |
|---|---|---|---|---|
| RIC vs MAC | ||||
| Before 6 months | 1.08 (0.85-1.35), P = .5401 | 0.91 (0.69-1.20), P = .4898 | 1.18 (0.88-1.59), P = .273 | 0.93 (0.64-1.34), P = .6824 |
| After 6 months | 1.43 (1.09-1.89), P = .0108 | 1.55 (1.19-2.01), P = .0009 | 1.47 (1.03-2.11), P = .0353 | 1.38 (0.89-2.14), P = .1476 |
| Age | ||||
| 10-y increase | 1.16 (1.06-1.27), P = .0009 | 1.22 (1.12-1.34), P < .0001 | 1.04 (0.93-1.15), P = .5273 | 1.42 (1.22-1.66), P < .0001 |
| Time from diagnosis to HCT | ||||
| 1-mo increase | 1 (1-1.01), P = .2125 | 1.01 (1-1.01), P = .1586 | 1.01 (1-1.02), P = .1015 | 1 (0.98-1.01), P = .9685 |
| Cytogenetic risk | ||||
| Intermediate | ref | ref | ref | ref |
| Poor | 1.75 (1.47-2.09), P < .0001 | 1.79 (1.49-2.15), P < .0001 | 2.09 (1.67-2.61), P < .0001 | 1.32 (0.98-1.77), P = .064 |
| HLA | ||||
| Identical sibling | ref | ref | ref | ref |
| URD 10/10 | 0.96 (0.8-1.16), P = .6649 | 1.12 (0.92-1.37), P = .2496 | 0.77 (0.61-0.98), P = .033 | 1.39 (1.02-1.89), P = .0386 |
| URD 9/10 | 1.36 (1.03-1.78), P = .0282 | 1.59 (1.2-2.11), P = .0014 | 1.05 (0.73-1.51), P = .7802 | 2.04 (1.34-3.1), P = .0009 |
| Donor to patient sex | ||||
| Other | ref | ref | ref | ref |
| Female to male | 1.01 (0.82-1.25), P = .9288 | 1 (0.8-1.25), P = .9749 | 0.87 (0.66-1.16), P = .3554 | 1.24 (0.9-1.72), P = .1882 |
| CMV patient | ||||
| Negative | ref | ref | ref | ref |
| Positive | 1.13 (0.93-1.37), P = .2069 | 1.14 (0.93-1.39), P = .2056 | 1.05 (0.82-1.34), P = .6966 | 1.27 (0.93-1.74), P = .1338 |
| CMV donor | ||||
| Negative | ref | ref | ref | ref |
| Positive | 1.04 (0.87-1.24), P = .6913 | 1.07 (0.89-1.29), P = .4515 | 1.15 (0.92-1.44), P = .2176 | 0.88 (0.66-1.17), P = .3838 |
| Cell source | ||||
| BM | ref | ref | ref | ref |
| PB | 0.99 (0.74-1.31), P = .9319 | 0.92 (0.69-1.22), P = .5618 | 0.99 (0.69-1.43), P = .9553 | 0.98 (0.62-1.54), P = .9371 |
| Disease status at HCT | ||||
| CR1 | ref | ref | ref | ref |
| CR2+ | 1.17 (0.78-1.74), P = .4436 | 1.25 (0.83-1.88), P = .2883 | 1.09 (0.64-1.85), P = .7602 | 1.3 (0.71-2.37), P = .3961 |
| Active | 1.5 (1.25-1.79), P < .0001 | 1.49 (1.24-1.8), P < .0001 | 1.57 (1.25-1.97), P = .0001 | 1.39 (1.05-1.86), P = .0225 |
| TCD | ||||
| No | ref | ref | ref | ref |
| ATG/alemtuzumab | 1.07 (0.89-1.29), P = .4588 | 1.14 (0.94-1.39), P = .1742 | 0.96 (0.76-1.22), P = .757 | 1.29 (0.95-1.75), P = .1052 |
| Year of HCT | ||||
| One-year increase | 1.01 (0.99-1.04), P = .3365 | 1.01 (0.99-1.04), P = .302 | 1.01 (0.98-1.05), P = .4074 | 1.01 (0.97-1.05), P = .6019 |
BM, bone marrow; dx, diagnosis; PB, peripheral blood; ref, reference category.